Correlation Between RYOHIN UNSPADR/1 and Takeda Pharmaceutical

Can any of the company-specific risk be diversified away by investing in both RYOHIN UNSPADR/1 and Takeda Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining RYOHIN UNSPADR/1 and Takeda Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between RYOHIN UNSPADR1 and Takeda Pharmaceutical, you can compare the effects of market volatilities on RYOHIN UNSPADR/1 and Takeda Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in RYOHIN UNSPADR/1 with a short position of Takeda Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of RYOHIN UNSPADR/1 and Takeda Pharmaceutical.

Diversification Opportunities for RYOHIN UNSPADR/1 and Takeda Pharmaceutical

0.34

Correlation Coefficient

RYOHIN UNSPADR/1  Takeda Pharmaceutical

Weak diversification

The 3 months correlation between RYOHIN and Takeda is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding RYOHIN UNSPADR1 and Takeda Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Takeda Pharmaceutical and RYOHIN UNSPADR/1 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on RYOHIN UNSPADR1 are associated (or correlated) with Takeda Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Takeda Pharmaceutical has no effect on the direction of RYOHIN UNSPADR/1 i.e., RYOHIN UNSPADR/1 and Takeda Pharmaceutical go up and down completely randomly.

Pair Corralation between RYOHIN UNSPADR/1 and Takeda Pharmaceutical

Assuming the 90 days trading horizon RYOHIN UNSPADR1 is expected to generate 1.69 times more return on investment than Takeda Pharmaceutical. However, RYOHIN UNSPADR/1 is 1.69 times more volatile than Takeda Pharmaceutical. It trades about 0.1 of its potential returns per unit of risk. Takeda Pharmaceutical is currently generating about 0.01 per unit of risk. If you would invest  932.00  in RYOHIN UNSPADR1 on December 2, 2024 and sell it today you would earn a total of  1,568  from holding RYOHIN UNSPADR1 or generate 168.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

RYOHIN UNSPADR1  vs.  Takeda Pharmaceutical

RYOHIN UNSPADR/1

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in RYOHIN UNSPADR1 are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile forward-looking signals, RYOHIN UNSPADR/1 reported solid returns over the last few months and may actually be approaching a breakup point.

Takeda Pharmaceutical

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Takeda Pharmaceutical are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain fundamental indicators, Takeda Pharmaceutical may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with RYOHIN UNSPADR/1 and Takeda Pharmaceutical

The main advantage of trading using opposite RYOHIN UNSPADR/1 and Takeda Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if RYOHIN UNSPADR/1 position performs unexpectedly, Takeda Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will offset losses from the drop in Takeda Pharmaceutical's long position.

The idea behind RYOHIN UNSPADR1 and Takeda Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.